KU-55933 (ATM Kinase Inhibitor)

Catalog No.S1092

KU-55933 (ATM Kinase Inhibitor) Chemical Structure

Molecular Weight(MW): 395.49

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

Size Price Stock Quantity  
In DMSO USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 36 Publications

4 Customer Reviews

  •  

    Effects of NVP-BKM120 and KU-55933 and their combination on the DNA damage response. A, HCC1937 cells were treated for 18 hours with NVP-BKM120 at 2.5 μmol/L, KU-55933 at 10 μmol/L, or their combination, subjected to ionizing radiation(IR) with 10 Gy or mock, lysed 6 hours later, and subjected to immunoblotting with antibodies as indicated.

    Cancer Discov 2012 2, 1048-1063. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

    Confocal immunostaining (left panel) graphical representation (right panel) for phosphorylation of S25-53BP1, which is known to be ATM dependent, at different time points following irradiation of HEK 293T parental and p18CycE-expressing cells in the absence or presence of the ATM inhibitor, KU55933. Error bars represent SD (n=3).

    Nucleic Acids Res 2011 41, 10157-69. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

  •  

    59PDb2 repression is restored in c22 by inhibition of DNAPKcs. Shown are representative ChIP QPCR of USF-1 binding at Db2 (A) and Db2 mRNA levels (B) in P5424-c22 1 d after treatment with the indicated kinase inhibitors.

    J Immunol 2012 188, 2266-2275. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

    effect of ATM inhibitor in etoposide-induced cell death. The cells were pretreated with KU55933 (2 μM) for 1 h before etoposide treatment.

     

     

    J Biol Chem 2011 286, 8394-8404. KU-55933 (ATM Kinase Inhibitor) purchased from Selleck.

Purity & Quality Control

Choose Selective ATM/ATR Inhibitors

Biological Activity

Description KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.
Targets
ATM [1]
(Cell-free assay)
12.9 nM
In vitro

KU-55933 inhibits DNA-PK and PI3K with IC50 of 2.5 μM and 16.6 μM, respectively. Besides, KU-55933 also prevents the activity of mTOR with IC50 of 9.3 μM. KU-55933 is active at the cellular level in ablating a well-characterized ATM-dependent phosphorylation event. KU-55933 has a dose-dependent effect in inhibiting this ATM-dependent phosphorylation event with IC50 of 300 nM. KU-58050 does not prevent the ATM-dependent phosphorylation of p53 serine 15 until a dose of 30 μM. Addition of KU-55933 has no appreciable effects on UV-induced phosphorylation of H2AX on serine 139, NBS1 on serine 343, CHK1 on serine 345, and SMC1 on serine 966. In stark contrast to the UV responses, KU-55933 ablates the ionizing radiation-induced phosphorylation of these ATM substrates. KU-55933 sensitizes HeLa cells to a range of ionizing radiation doses. [1] KU-55933 inhibits the phosphorylation of Akt induced by growth factors in cancer cells. KU-55933 suppresses the proliferation of cancer cells. Furthermore, suppression of ATM by KU-55933 improves survival, probably via prevention of downstream activation of TAp63α. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-145 M2fMNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j3UWlEPTB;Mz6yO|M2OiEQvF2= MY\TRW5ITVJ?
HuO-3N1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfUSJc3UUN3ME20MlE4OTR{IN88US=> M2jScHNCVkeHUh?=
LAMA-84 NWjuOFhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2WzcGlEPTB;ND61PFQ3PSEQvF2= Mlf4V2FPT0WU
CAL-72 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTVwNEiwPFQh|ryP MWHTRW5ITVJ?
LoVo MnfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4[5S2lEPTB;Nj65N|I{QSEQvF2= MoTtV2FPT0WU
HH NIj1OGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRThwMke2O|Eh|ryP NGnzeGFUSU6JRWK=
SK-MEL-3 M2Tvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\LPGFFUUN3ME24MlI5PTd3IN88US=> MXXTRW5ITVJ?
KM12 Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmD1TWM2OD17LkKxNVQzKM7:TR?= MV\TRW5ITVJ?
NCI-H1437 M1LCU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjsSIhFUUN3ME25MlgxQTdizszN MkLZV2FPT0WU
NCI-H1838 M1Hm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn6yTWM2OD1zMT6xPFY2KM7:TR?= M1TU[nNCVkeHUh?=
J-RT3-T3-5 M{LvfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTFzLkK0NVch|ryP MYPTRW5ITVJ?
GOTO NV2wbJRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjUSFJKSzVyPUGxMlY6QTZizszN NXr3TnRqW0GQR1XS
LB2241-RCC MonQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTXTWM2OD1zMT63NVg3KM7:TR?= MYnTRW5ITVJ?
ES7 M3rKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnkRVdKSzVyPUGxMlc5QCEQvF2= MkPiV2FPT0WU
KP-N-YS MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\0SopKSzVyPUGyMlY{PTRizszN NHvLcmFUSU6JRWK=
CAL-12T MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLWTWM2OD1zMz62NVch|ryP MlfTV2FPT0WU
COLO-684 NULoblZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHSVVU5UUN3ME2xOE4yPTZ7IN88US=> MXTTRW5ITVJ?
DOK MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fEfWlEPTB;MUWuN|MzQSEQvF2= M1TDR3NCVkeHUh?=
Hs-578-T NEDLOJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHUfnNKSzVyPUG1MlQyQDJizszN NEjGWoFUSU6JRWK=
D-423MG NYSxbYI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnEWYxKSzVyPUG1MlUzOzZizszN NFfpbW9USU6JRWK=
DBTRG-05MG NVjlfJdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHJS|lVUUN3ME2xOU43OTFzIN88US=> MlPpV2FPT0WU
VM-CUB-1 M3W5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjoOXdyUUN3ME2xOU46QDR7IN88US=> NGmz[JZUSU6JRWK=
KG-1 NUDaVIdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHCTWM2OD1zNj6wPVk3KM7:TR?= MX\TRW5ITVJ?
8305C NXX6UmZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELy[ZpKSzVyPUG2MlE5QDlizszN MlzyV2FPT0WU
HuH-7 NHnpNoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTF4LkK2O|Qh|ryP M2GyPHNCVkeHUh?=
LXF-289 NWT4U|ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHDcphKSzVyPUG2MlI4PDdizszN NYj3WJBsW0GQR1XS
NCI-H1793 M2XVeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3sTWM2OD1zNj60O|EzKM7:TR?= MYXTRW5ITVJ?
ChaGo-K-1 NFLtS49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3OTWM2OD1zNj62OVY5KM7:TR?= MnjOV2FPT0WU
GCIY NUPyS2F4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnNdmtKSzVyPUG2Mlc6ODVizszN M4\YbHNCVkeHUh?=
SK-MEL-28 Moi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTF5LkC0O|Uh|ryP NHPnN5VUSU6JRWK=
NCI-SNU-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTF5LkGyOlkh|ryP MX7TRW5ITVJ?
CTB-1 NILSemlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1P0e2lEPTB;MUeuNlI2QSEQvF2= M4PxWXNCVkeHUh?=
NCI-H82 M1vwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnv3TWM2OD1zNz60OVc{KM7:TR?= MnnQV2FPT0WU
HCC2998 MlfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnKSFBFUUN3ME2xO{43PzN|IN88US=> MkP1V2FPT0WU
NCI-H2030 M3;xbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7kSnhtUUN3ME2xPE4yQTl5IN88US=> M1LmfnNCVkeHUh?=
HuP-T3 M3XyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWj3TGpMUUN3ME2xPE42QDh6IN88US=> MX;TRW5ITVJ?
697 NWf2W5d2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTF7LkCyNFEh|ryP MlnwV2FPT0WU
MLMA M2W4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTF7LkC1OVch|ryP NELUR41USU6JRWK=
HCC70 NFPqUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWK0[m5XUUN3ME2xPU41QDlizszN NIDyUHdUSU6JRWK=
A704 M3LjU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7ITWM2OD1zOT64N|A2KM7:TR?= M1zHOHNCVkeHUh?=
D-283MED NXH2cHBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrxZ|BKSzVyPUKwMlU{OzlizszN MnrUV2FPT0WU
U031 M1n4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXaTWM2OD1{MT6xOFg6KM7:TR?= MUTTRW5ITVJ?
HSC-3 NV\aPWRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTJzLkG4N|Uh|ryP NGSyUGJUSU6JRWK=
JVM-3 MlfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;qPFRKSzVyPUKyMlUxPiEQvF2= NW\VbIpHW0GQR1XS
Mewo MmjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTJ{LkWwO|Mh|ryP MmHNV2FPT0WU
YH-13 NVPEfHM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1q0OGlEPTB;MkKuOVEzOyEQvF2= MWLTRW5ITVJ?
LB1047-RCC Ml\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7wTWM2OD1{Mj61PFc6KM7:TR?= M4D5ZnNCVkeHUh?=
HCC2157 NYn2TplsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTJ{LkiwOVQh|ryP NH3teolUSU6JRWK=
SNU-449 NWTFbZdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrZTWM2OD1{Mj64O|Q5KM7:TR?= MWLTRW5ITVJ?
Ramos-2G6-4C10 NFTIcopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTJ{Lkm2JO69VQ>? M3nSUnNCVkeHUh?=
CHL-1 M4nySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M173e2lEPTB;MkOuO|I6OiEQvF2= NFO1e5hUSU6JRWK=
SK-MEL-30 Mn;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWf6PIJYUUN3ME2yOE41PjZ{IN88US=> NYK2VYREW0GQR1XS
PANC-08-13 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;tTWM2OD1{NT6wPVM5KM7:TR?= NF\WZoRUSU6JRWK=
QIMR-WIL NEHySXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3KWmg5UUN3ME2yOU4yQDV6IN88US=> MWnTRW5ITVJ?
BFTC-905 NGTWZ4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3iTWM2OD1{NT61PVQ1KM7:TR?= Mmm3V2FPT0WU
GI-1 MmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXpTWM2OD1{NT63NFU2KM7:TR?= NV34cpFGW0GQR1XS
MDA-MB-415 M4W5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfRXHhKSzVyPUK2MlUxOzNizszN NYTmWIVHW0GQR1XS
GT3TKB NGXDNoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzYeWoyUUN3ME2yOk42OzR{IN88US=> NVrWOZRIW0GQR1XS
DEL MlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;oXoJOUUN3ME2yOk45OzV4IN88US=> NUjo[3hTW0GQR1XS
KOSC-2 M2XNOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:yTWM2OD1{Nj65NFc2KM7:TR?= MVPTRW5ITVJ?
RVH-421 NH[0WJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTtV5JKSzVyPUK3MlI6OjFizszN M1joSXNCVkeHUh?=
EW-13 NYnaPXlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLSVIdKSzVyPUK3MlQ{ODhizszN MWnTRW5ITVJ?
639-V NEW4WYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HabWlEPTB;MkeuOVEyQSEQvF2= MkPkV2FPT0WU
A2780 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2j6d2lEPTB;MkeuOlQyKM7:TR?= MmPOV2FPT0WU
SW982 Mlv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmi0TWM2OD1{Nz65NFUzKM7:TR?= NIqzS3JUSU6JRWK=
SW1710 NWPmfYRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX[zPYdrUUN3ME2yPE4xQThzIN88US=> M4Ln[3NCVkeHUh?=
HCC1569 MlvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTJ6LkS4PVch|ryP MoDsV2FPT0WU
MV-4-11 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTObWhKUUN3ME2yPE42PzN3IN88US=> NUXIU3hbW0GQR1XS
BHT-101 MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF32UoJKSzVyPUK4MlY2PzJizszN MWTTRW5ITVJ?
Ca9-22 NEXSSVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7OdIx1UUN3ME2yPE44OTRizszN MXvTRW5ITVJ?
HAL-01 NGDM[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33tb2lEPTB;MkiuO|YyPSEQvF2= NG\SbXRUSU6JRWK=
D-263MG NFSxOmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TScGlEPTB;MkmuN|Q1KM7:TR?= M1T3THNCVkeHUh?=
NEC8 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PHfWlEPTB;MkmuOVU1QCEQvF2= MXvTRW5ITVJ?
EKVX NYn1XYpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DrSGlEPTB;M{GuOVg1PyEQvF2= M1jlenNCVkeHUh?=
EM-2 Mn[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnjNoFKSzVyPUOxMlY{ODRizszN NXzyU5U{W0GQR1XS
MFM-223 NX6zSpdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlq0TWM2OD1|MT64NFk5KM7:TR?= NEWzVHhUSU6JRWK=
SK-PN-DW MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPITWM2OD1|Mj6xOFA3KM7:TR?= M1jVTnNCVkeHUh?=
HuO9 NGn4ZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\lTWM2OD1|Mj61NlgzKM7:TR?= Ml;2V2FPT0WU
MHH-PREB-1 NEjXWXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rPfWlEPTB;M{KuOlI{PCEQvF2= NYLmUoJ7W0GQR1XS
OVCAR-4 M4\4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUSwRXhDUUN3ME2zNk45OzZ|IN88US=> M2LOZ3NCVkeHUh?=
NCI-H1648 NFnMR4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPoTWM2OD1|Mj64OlUyKM7:TR?= NXu0OVQ4W0GQR1XS
MKN1 M37y[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTN2LkGxNFEh|ryP NFHtUZNUSU6JRWK=
KYSE-450 M2PEcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTFTWM2OD1|ND62OFQ1KM7:TR?= MYXTRW5ITVJ?
ES8 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXz3eWROUUN3ME2zOE45QTd3IN88US=> M2fwV3NCVkeHUh?=
MS-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXDOmtKSzVyPUO0Mlk2PTRizszN NYPIbnU6W0GQR1XS
HOP-92 MnrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XQ[2lEPTB;M{WuPVI4PyEQvF2= NEHWVmlUSU6JRWK=
SKG-IIIa NHj0WnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVflTY1wUUN3ME2zOk4zPTZzIN88US=> NFP0SGNUSU6JRWK=
TE-11 NEO1bZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoC3TWM2OD1|Nj61NlQ{KM7:TR?= NFzGfXpUSU6JRWK=
SK-NEP-1 M{Hl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzYTWM2OD1|Nz62O|Q1KM7:TR?= MmDCV2FPT0WU
DB MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4i2N2lEPTB;M{euPVE5PSEQvF2= NGjtN3pUSU6JRWK=
IA-LM M1i1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjwWHd7UUN3ME2zPE4xOjN7IN88US=> NUDiSlB2W0GQR1XS
COLO-829 MnXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fYWGlEPTB;M{iuOFE2QSEQvF2= NYH2NGF6W0GQR1XS
TGBC11TKB Mo\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTQPG54UUN3ME2zPU4yPDB6IN88US=> NXvqNVd3W0GQR1XS
CAL-51 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTRyLkC2NVIh|ryP MmTnV2FPT0WU
NCI-H2228 M17ZZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fDWmlEPTB;NECuN|Y3OiEQvF2= MljqV2FPT0WU
C32 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;hTWM2OD12MD60NFI1KM7:TR?= M4ntOHNCVkeHUh?=
KU-19-19 NWf1fZRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTRyLke2PFMh|ryP M1LrTXNCVkeHUh?=
KNS-62 M37sVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTRyLkizPFEh|ryP MlLwV2FPT0WU
FADU MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTRzLkK1NFIh|ryP MVPTRW5ITVJ?
CAL-33 MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nFNGlEPTB;NEKuOlc1QSEQvF2= M1X5cnNCVkeHUh?=
CHP-134 Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPHTWM2OD12Mj64OFk3KM7:TR?= MWDTRW5ITVJ?
HDLM-2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTR{LkmwPFQh|ryP NHjXfphUSU6JRWK=
NBsusSR MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjUT3p{UUN3ME20N{4xPzJ3IN88US=> NYH2eVNJW0GQR1XS
SW954 Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXPTWM2OD12Mz6xNFU{KM7:TR?= NYPT[JliW0GQR1XS
HCC1806 M3vVcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTR|LkSxNUDPxE1? NFj2cmlUSU6JRWK=
VMRC-RCZ MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTiNllpUUN3ME20N{41PTh4IN88US=> NFe1Xo1USU6JRWK=
A549 Mk[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTR|LkmzNUDPxE1? MXjTRW5ITVJ?
NKM-1 NEfZS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fuXGlEPTB;NEOuPVU2QCEQvF2= Ml7RV2FPT0WU
DMS-273 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTR2Lke1Olch|ryP NETjSYpUSU6JRWK=
TYK-nu NEPBSWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M370NWlEPTB;NEWuNVI{PCEQvF2= NXzPSVlUW0GQR1XS
KALS-1 NGrJcHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTR3LkG0OkDPxE1? MVrTRW5ITVJ?
A101D MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3e5SWlEPTB;NEWuOFQ2PiEQvF2= MnG4V2FPT0WU
G-361 Moi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPwUJQyUUN3ME20Ok4zOTN6IN88US=> M4TzNHNCVkeHUh?=
KARPAS-299 Ml[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTR4LkO1NVYh|ryP MonFV2FPT0WU
RS4-11 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4O3PWlEPTB;NE[uOVQzKM7:TR?= NY\UU3FTW0GQR1XS
HT-1376 M3TCfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zHfGlEPTB;NE[uO|QzPiEQvF2= M3L0TXNCVkeHUh?=
SK-N-AS NFTYUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTR4Lke4NlIh|ryP NYi4OoVwW0GQR1XS
MG-63 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4WxeWlEPTB;NE[uPVA{PiEQvF2= Mnv1V2FPT0WU
EPLC-272H MmK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXmZZZlUUN3ME20Ok46PTB|IN88US=> NY\KOpEzW0GQR1XS
BALL-1 NITDZXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzyTWM2OD12Nz64N|Ih|ryP Mmf2V2FPT0WU
LCLC-97TM1 M1fvPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\LelJtUUN3ME20PE4zODJizszN MUHTRW5ITVJ?
HO-1-N-1 M4XMPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVKybWRoUUN3ME20PE46Pjd4IN88US=> M{ixXnNCVkeHUh?=
MFE-280 MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTR7LkS2NVch|ryP MXnTRW5ITVJ?
NCI-H526 NUHBSnZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPxSFdKSzVyPUS5MlgyPjNizszN MmeyV2FPT0WU
D-566MG Mm\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIW2RmZKSzVyPUS5MlkxQTZizszN M2HOR3NCVkeHUh?=
BB30-HNC M4jabGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnEb4NKSzVyPUS5Mlk1QThizszN NW\1O3ROW0GQR1XS
SK-N-DZ M{XnbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1yyTmlEPTB;NUCuNFQ5OSEQvF2= MYTTRW5ITVJ?
HepG2  M3nB[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXZNVDDqM7:TR?= MYOyOEBp M1L4SYJtd2OtczDTR{1KUUl|LXnu[JVk\WRiUzDwbIF{\SCjcoLld5Q> NFnEZpAzPTV{N{GyNy=>
HepG2  NHjNZ2ZHfW6ldHnvckBCe3OjeR?= NHnaPY0yOMLizszN NGiwSVEzPCCq Mn3td5VxeHKnc4Pld{B1cGVicHjvd5Bpd3K7bHH0bY9veyCxZjDBWG0hd25iU3XyNVk5OSxiQ3jrNUBwdiCVZYKzOFUtKEOqa{Kgc44hXGi{NkisJIFv\CCFZHuyJI9vKFS7ckG1JIlv\HWlZXSgZpkhW0NvSVnJNy=> MnHYNlU2OjdzMkO=
KATO III  M3XNTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jmPVIvPS93L{euOUDPxE1? MYLEUXNQ NX25PZFt\W6qYX7j[ZMhfGinIITvfIlkcXS7IH;mJI9t[XCjcnni M1HaZ|I1QDRzN{G4
hTCEpi MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX2xNEDPxE1? NWT3SXB4TE2VTx?= M4Pub5Bz\X[nboTzJJRp\SCleYTvdIF1cGmlIHXm[oVkfCCxZjDIV3YuOQ>? NH7HTGszPDN5MEizOS=>
MCF10A NUK5O5RpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrjPGw3OTBizszN M1PXfFI1KGh? MWTEUXNQ M1PBOJBwfGWwdHnheIV{KHSqZTDjfZRwfG:6aXPpeJkhd2ZiR1G= NXfMXYx5OjRzNUC1PVU>
HL-60  NHzBdmNHfW6ldHnvckBCe3OjeR?= M4D3fVExKM7:TR?= MonUNE42KGh? MWDEUXNQ MnjOdoVlfWOnczDwbI9{eGixconsZZRqd25ib3[gR4hsOsLi MU[yN|k{PDRzMR?=
MCF-7 M175eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGX6fmMyNTFyMN88US=> NH61boYzPCCq NUW2eHpmTkKV NXXpfo43cW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbh?= MnnrNlMyQDV|NEe=
HeLa  Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVuxMVExOM7:TR?= MnvRNlQhcA>? MkXQSmJU MljHbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdg>? NYHBb4JFOjNzOEWzOFc>
SH-SY5Y MXfGeY5kfGmxbjDBd5NigQ>? MVexNOKh|ryPwrC= MkDtNlQhcA>? MWLpcohq[mm2czDjcIlweXWrbn;sMYlv\HWlZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJJA2Ow>? NGrtNZEzOjZ{N{K5OC=>
IMR-32 M4q1R2Z2dmO2aX;uJGF{e2G7 MYqxNOKh|ryPwrC= Mn:1NlQhcA>? MorUbY5pcWKrdIOgZ4xqd3G3aX7vcE1qdmS3Y3XkJJBpd3OyaH;yfYxifGmxbjDv[kBxPTN? MYSyNlYzPzJ7NB?=
A549 MXvGeY5kfGmxbjDBd5NigQ>? M1nDT|ExyqEQvF5CpC=> NV;ISYcyOSCq MlH1d5VxeHKnc4Pld{BP[W6xLVPvMYlv\HWlZXSgdFU{KGGlY4XteYxifGmxbh?= NEXsSpgzOjV3OUOyNS=>
T47D  NVrGd4IxTnWwY4Tpc44hSXO|YYm= MmTTNlDDqG2P NGnUZmYzPCCq NEjlU3BFVVOR MU\wdoV3\W62czDJVk1qdmS3Y3XkJIRm\3KjZHH0bY9vKG:oIFpOvmLPuQ>? Ml3uNlEyPDR6MEW=
A29 MEF NXmzWVZjTnWwY4Tpc44hSXO|YYm= M3zhZVExyqEQvF5CpC=> NILnXHYycA>? NX3YUllI[myxY3vzxsB1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFHreEBifCCVZYK0O|PDqA>? NIPPO3UzODB3M{e4NS=>
MDA-MB-453  NV21ZnVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEW2XFY2NTRyIN88US=> MV23NkBp MUfJR|UxKG:oIEGwJO69VQ>? MnvmNlAxPTN5OEG=
PC-3 NWnPZWJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4T3NlUuPDBizszN M320T|czKGh? NX7tbG5MUUN3MDDv[kAyOCEQvF2= M1nJVVIxODV|N{ix

... Click to View More Cell Line Experimental Data

In vivo Suppression of ATM-dependent STAT3 activation by KU-55933 enhances TRAIL-mediated apoptosis through up-regulation of surface DR5 expression, whereas suppression of both STAT3 and NF-κB appeares to be involved in down-regulation of cFLIP accompanied by an additional increase in apoptotic levels. The ATM inhibitor KU-55933 affectes TRAIL-mediated apoptosis more strongly than the JAK2 inhibitor, AG490, or overexpression of STAT3β. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Purified enzyme assays:

ATM for use in the in vitro assay is obtained from HeLa nuclear extract by immunoprecipitation with rabbit polyclonal antiserum raised to the COOH-terminal 400 amino acids of ATM in buffer containing 25 mM HEPES (pH 7.4), 2 mM MgCl2, 250 mM KCl, 500 μM EDTA, 100 μM Na3VO4, 10% v/v glycerol, and 0.1% v/v Igepal. ATM-antibody complexes are isolated from nuclear extract by incubating with protein A-Sepharose beads for 1 hour and then through centrifugation to recover the beads. In the well of a 96-well plate, ATM-containing Sepharose beads are incubated with 1 μg of substrate glutathione S-transferase–p53N66 (NH2-terminal 66 amino acids of p53 fused to glutathione S-transferase) in ATM assay buffer [25 mM HEPES (pH 7.4), 75 mM NaCl, 3 mM MgCl2, 2 mM MnCl2, 50 μM Na3VO4, 500 μM DTT, and 5% v/v glycerol] at 37 °C in the presence or absence of inhibitor. After 10 minutes with gentle shaking, ATP is added to a final concentration of 50 μM and the reaction continued at 37 °C for an additional 1 hour. The plate is centrifuged at 250 × g for 10 minutes (4 °C) to remove the ATM-containing beads, and the supernatant is removed and transferred to a white opaque 96-well plate and incubated at room temperature for 1.5 hours to allow glutathione S-transferase-p53N66 binding. This plate is then washed with PBS, blotted dry, and analyzed by a standard ELISA technique with a phospho-serine 15 p53 antibody. The detection of phosphorylated glutathione S-transferase-p53N66 substrate is performed in combination with a goat antimouse horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence solution is used to produce a signal and chemiluminescent detection is carried out.
Cell Research:

[1]

+ Expand
  • Cell lines: U2OS cells
  • Concentrations: 10 μM
  • Incubation Time: 2 hours
  • Method:

    U2OS cells are exposed to ionizing radiation (3, 5, or 15 Gy) or UV (5 or 50 J/m2) and the ATM response determined by Western blot analysis of p53 serine 15 phosphorylation and stabilization of wild-type p53. Whole cell extracts are obtained from each time point, proteins separated by SDS-PAGE, and the ATM-specific increase in phosphorylated serine 15 measured with a p53 phospho-serine 15 specific antibody. Overall p53 stabilization with time is also observed with a p53-specific antibody (DO-1). Similarly, for studying ATM-dependent phosphorylations on H2AX, CHK1, NBS1, and SMC1, the following antibodies are used: CHK1 phospho-serine 345 and NBS1 phospho-serine 343 antibodies. Histone H2A (H-124) and CHK1 antibodies are also used, as well as SMC1 and SMC1 phospho-serine 966 antibodies. For determination of a cellular IC50 for KU-55933, the peak response time for p53 serine 15 phosphorylation of 2 hours is used to monitor inhibition of ATM. KU-55933 is titrated onto cells and preincubated for 1 hour before ionizing radiation. Using scanning densitometry, the percentage inhibition relative to vehicle control is calculated, and the IC50 value is calculated as for the in vitro determinations.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: BALB/c nu/nu nude mice bearing LU1205 cells
  • Formulation: --
  • Dosages: 10 μM
  • Administration: --
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 33 mg/mL (83.44 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO and 47.5% PEG300
For best results, use promptly after mixing.
10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 395.49
Formula

C21H17NO3S2

CAS No. 587871-26-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATM/ATR Signaling Pathway Map

ATM/ATR Inhibitors with Unique Features

Related ATM/ATR Products

Tags: buy KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) supplier | purchase KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) cost | KU-55933 (ATM Kinase Inhibitor) manufacturer | order KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID